Tag Archive for: UCB

Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024

/in

Berlin, Germany, 4 April 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces that it will be presenting a poster, demonstrating its new findings on the discovery of novel macrocyclic peptide radioligands for tumor therapy by mRNA display in collaboration with research […]

Read more

UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer

/in

UCB’s expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity™, will aid Ariceum’s discovery of treatments for solid tumors Ariceum’s expertise in radiopharmaceuticals and labelling technology will aid UCB’s discovery of treatments for immune-related diseases Potential to expand Ariceum’s pipeline with three new programs at discovery stage Berlin, Germany, and Brussels, Belgium, 11 […]

Read more